Compare STXS & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STXS | MOLN |
|---|---|---|
| Founded | 1990 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 210.0M | 157.8M |
| IPO Year | 2004 | 2021 |
| Metric | STXS | MOLN |
|---|---|---|
| Price | $2.40 | $3.96 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $4.00 | $3.75 |
| AVG Volume (30 Days) | ★ 471.8K | 2.3K |
| Earning Date | 11-11-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $30,075,000.00 | N/A |
| Revenue This Year | $24.48 | N/A |
| Revenue Next Year | $29.98 | $1,000.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 19.62 | N/A |
| 52 Week Low | $1.54 | $3.36 |
| 52 Week High | $3.59 | $5.91 |
| Indicator | STXS | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 46.98 | 49.56 |
| Support Level | $2.32 | $3.92 |
| Resistance Level | $2.44 | $4.35 |
| Average True Range (ATR) | 0.09 | 0.17 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 70.37 | 37.68 |
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.